In vivo verification of tumor suppressors and their interactions with each other has required complex experiments. A report in this issue uses a novel CRISPR–Cas9 technology with barcodes to test, in parallel, the tumorigenic potential of functional loss of multiple tumor-suppressor genes in the context of a genetically engineered mouse model of lung adenocarcinoma with mutant Kras.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cancer Genome Atlas Research Network. Nature 489, 519–525 (2012).
Cancer Genome Atlas Research Network. Nature 511, 543–550 (2014).
Ettinger, D. S. et al. J. Natl. Compr. Canc. Netw. 15, 504–535 (2017).
George, J. et al. Nature 524, 47–53 (2015).
Steuer, C. E. & Ramalingam, S. S. J. Clin. Oncol. 36, 631–632 (2018).
Zehir, A. et al. Nat. Med. 23, 703–713 (2017).
Rogers, Z. N. et al. Nat. Genet. https://doi.org/10.1038/s41588-018-0083-2 (2018).
Rogers, Z. N. et al. Nat. Methods 14, 737–742 (2017).
Sánchez-Rivera, F. J. et al. Nature 516, 428–431 (2014).
Walter, D. M. et al. Cancer Res. 77, 1719–1729 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kim, J., Minna, J.D. Evaluating tumor-suppressor gene combinations. Nat Genet 50, 480–482 (2018). https://doi.org/10.1038/s41588-018-0095-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-018-0095-y
